Arcutis Biotherapeutics, Inc. (ARQT)

8,75 +0,01 (+0,11%) Börsenschluss: 04:00PM EDT

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road
Suite 300
Westlake Village, CA 91361
United States
805 418 5006
https://www.arcutis.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 296

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Todd Franklin Watanabe M.A.	President, CEO & Director	1,01M	271,89k	1968
Dr. Bhaskar Chaudhuri Ph.D.	Co-Founder & Independent Director	59,67k	N/A	1955
Mr. Masaru Matsuda Esq., J.D.	Senior VP, General Counsel & Corporate Secretary	626,22k	N/A	1971
Dr. Patrick E. Burnett M.D., Ph.D.	Senior VP & Chief Medical Officer	689,95k	N/A	1972
Mr. David J. Topper	Chief Financial Officer	N/A	N/A	1958
Mr. Rajvir Madan	Chief Digital & Technology Officer	N/A	N/A	N/A
Ms. Latha Vairavan	Vice President of Finance & Investor Relations	N/A	N/A	N/A
Ms. Courtney Barton	VP and Chief Compliance Officer & Privacy Officer	N/A	N/A	1983
Ms. Amanda Sheldon	Head of Corporate Communications	N/A	N/A	N/A
Ms. Ayisha Jeter	Head of Marketing & Market Access	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Corporate Governance

Arcutis Biotherapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 6, Vorstand: 5, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.